A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer. - Contacts and Locations

A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.

This study has been completed.

Study NCT00042679. Last updated on July 18, 2006. Information provided by Eli Lilly and Company

Please refer to this study by its ClinicalTrials.gov identifier: NCT00042679

Locations


United States, California

	Berkeley, California, United States

	Bakersfield, California, United States

	Torrance, California, United States

United States, Florida

	Miami Beach, Florida, United States

United States, Illinois

	Park Ridge, Illinois, United States

	Chicago, Illinois, United States

United States, Maryland

	Baltimore, Maryland, United States

United States, Tennessee

	Chattanooga, Tennessee, United States

United States, Texas

	Lubbock, Texas, United States

United States, Virginia

	Charlottesville, Virginia, United States

United States, Wisconsin

	Milwaukee, Wisconsin, United States

Sponsors and Collaborators

Eli Lilly and Company